ClinicalTrials.gov record
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
ClinicalTrials.gov ID: NCT01694771
Public ClinicalTrials.gov record NCT01694771. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler® as Spiriva Handihaler®), compared to tiotropium (Spiriva Handihaler®) monotherapy on lung function in patients with COPD.
Study identification
- NCT ID
- NCT01694771
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,134 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2012
- Primary completion
- Jul 31, 2013
- Completion
- Jul 31, 2013
- Last update posted
- Sep 3, 2014
2012 – 2013
United States locations
- U.S. sites
- 90
- U.S. states
- 31
- U.S. cities
- 82
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1222.51.01055 Boehringer Ingelheim Investigational Site | Florence | Alabama | — | — |
| 1222.51.01087 Boehringer Ingelheim Investigational Site | Jasper | Alabama | — | — |
| 1222.51.01066 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 1222.51.01069 Boehringer Ingelheim Investigational Site | Scottsdale | Arizona | — | — |
| 1222.51.01040 Boehringer Ingelheim Investigational Site | Anaheim | California | — | — |
| 1222.51.01064 Boehringer Ingelheim Investigational Site | Encinitas | California | — | — |
| 1222.51.01060 Boehringer Ingelheim Investigational Site | Fullerton | California | — | — |
| 1222.51.01084 Boehringer Ingelheim Investigational Site | Lincoln | California | — | — |
| 1222.51.01041 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 1222.51.01094 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 1222.51.01015 Boehringer Ingelheim Investigational Site | Torrance | California | — | — |
| 1222.51.01052 Boehringer Ingelheim Investigational Site | Boulder | Colorado | — | — |
| 1222.51.01010 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 1222.51.01042 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 1222.51.01070 Boehringer Ingelheim Investigational Site | Stamford | Connecticut | — | — |
| 1222.51.01006 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1222.51.01021 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1222.51.01082 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1222.51.01065 Boehringer Ingelheim Investigational Site | DeLand | Florida | — | — |
| 1222.51.01051 Boehringer Ingelheim Investigational Site | Jacksonville | Florida | — | — |
| 1222.51.01092 Boehringer Ingelheim Investigational Site | Jacksonville | Florida | — | — |
| 1222.51.01081 Boehringer Ingelheim Investigational Site | Ormond Beach | Florida | — | — |
| 1222.51.01054 Boehringer Ingelheim Investigational Site | Panama City | Florida | — | — |
| 1222.51.01062 Boehringer Ingelheim Investigational Site | Pensacola | Florida | — | — |
| 1222.51.01088 Boehringer Ingelheim Investigational Site | Port Orange | Florida | — | — |
| 1222.51.01079 Boehringer Ingelheim Investigational Site | Tamarac | Florida | — | — |
| 1222.51.01075 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 1222.51.01076 Boehringer Ingelheim Investigational Site | Austell | Georgia | — | — |
| 1222.51.01057 Boehringer Ingelheim Investigational Site | Duluth | Georgia | — | — |
| 1222.51.01086 Boehringer Ingelheim Investigational Site | Lawrenceville | Georgia | — | — |
| 1222.51.01019 Boehringer Ingelheim Investigational Site | Coeur d'Alene | Idaho | — | — |
| 1222.51.01027 Boehringer Ingelheim Investigational Site | Eagle | Idaho | — | — |
| 1222.51.01048 Boehringer Ingelheim Investigational Site | Arlingron Heights | Illinois | — | — |
| 1222.51.01044 Boehringer Ingelheim Investigational Site | River Forest | Illinois | — | — |
| 1222.51.01043 Boehringer Ingelheim Investigational Site | Skokie | Illinois | — | — |
| 1222.51.01090 Boehringer Ingelheim Investigational Site | Louisville | Kentucky | — | — |
| 1222.51.01023 Boehringer Ingelheim Investigational Site | Lafayette | Louisiana | — | — |
| 1222.51.01071 Boehringer Ingelheim Investigational Site | Opelousas | Louisiana | — | — |
| 1222.51.01050 Boehringer Ingelheim Investigational Site | North Dartmouth | Massachusetts | — | — |
| 1222.51.01049 Boehringer Ingelheim Investigational Site | Ann Arbor | Michigan | — | — |
| 1222.51.01025 Boehringer Ingelheim Investigational Site | Livonia | Michigan | — | — |
| 1222.51.01078 Boehringer Ingelheim Investigational Site | Edina | Minnesota | — | — |
| 1222.51.01033 Boehringer Ingelheim Investigational Site | Fridley | Minnesota | — | — |
| 1222.51.01074 Boehringer Ingelheim Investigational Site | Saint Charles | Missouri | — | — |
| 1222.51.01037 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1222.51.01039 Boehringer Ingelheim Investigational Site | Reno | Nevada | — | — |
| 1222.51.01045 Boehringer Ingelheim Investigational Site | Larchmont | New York | — | — |
| 1222.51.01018 Boehringer Ingelheim Investigational Site | Rochester | New York | — | — |
| 1222.51.01014 Boehringer Ingelheim Investigational Site | Asheville | North Carolina | — | — |
| 1222.51.01077 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| 1222.51.01056 Boehringer Ingelheim Investigational Site | Greensboro | North Carolina | — | — |
| 1222.51.01032 Boehringer Ingelheim Investigational Site | Canton | Ohio | — | — |
| 1222.51.01011 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1222.51.01005 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 1222.51.01093 Boehringer Ingelheim Investigational Site | Dayton | Ohio | — | — |
| 1222.51.01089 Boehringer Ingelheim Investigational Site | Sylvania | Ohio | — | — |
| 1222.51.01080 Boehringer Ingelheim Investigational Site | Toledo | Ohio | — | — |
| 1222.51.01017 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 1222.51.01047 Boehringer Ingelheim Investigational Site | Tulsa | Oklahoma | — | — |
| 1222.51.01031 Boehringer Ingelheim Investigational Site | Corvallis | Oregon | — | — |
| 1222.51.01020 Boehringer Ingelheim Investigational Site | Medford | Oregon | — | — |
| 1222.51.01053 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 1222.51.01016 Boehringer Ingelheim Investigational Site | Erie | Pennsylvania | — | — |
| 1222.51.01004 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1222.51.01030 Boehringer Ingelheim Investigational Site | East Providence | Rhode Island | — | — |
| 1222.51.01009 Boehringer Ingelheim Investigational Site | Johnston | Rhode Island | — | — |
| 1222.51.01036 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1222.51.01061 Boehringer Ingelheim Investigational Site | Columbia | South Carolina | — | — |
| 1222.51.01038 Boehringer Ingelheim Investigational Site | Easley | South Carolina | — | — |
| 1222.51.01046 Boehringer Ingelheim Investigational Site | Easley | South Carolina | — | — |
| 1222.51.01022 Boehringer Ingelheim Investigational Site | Gaffney | South Carolina | — | — |
| 1222.51.01063 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1222.51.01013 Boehringer Ingelheim Investigational Site | Greer | South Carolina | — | — |
| 1222.51.01024 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1222.51.01012 Boehringer Ingelheim Investigational Site | Union | South Carolina | — | — |
| 1222.51.01008 Boehringer Ingelheim Investigational Site | Rapid City | South Dakota | — | — |
| 1222.51.01035 Boehringer Ingelheim Investigational Site | Johnson City | Tennessee | — | — |
| 1222.51.01028 Boehringer Ingelheim Investigational Site | Boerne | Texas | — | — |
| 1222.51.01083 Boehringer Ingelheim Investigational Site | Corsicana | Texas | — | — |
| 1222.51.01085 Boehringer Ingelheim Investigational Site | Killeen | Texas | — | — |
| 1222.51.01073 Boehringer Ingelheim Investigational Site | Longview | Texas | — | — |
| 1222.51.01003 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1222.51.01058 Boehringer Ingelheim Investigational Site | Murray | Utah | — | — |
| 1222.51.01068 Boehringer Ingelheim Investigational Site | Abingdon | Virginia | — | — |
| 1222.51.01029 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1222.51.01034 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1222.51.01072 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1222.51.01091 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
| 1222.51.01002 Boehringer Ingelheim Investigational Site | Vancouver | Washington | — | — |
| 1222.51.01001 Boehringer Ingelheim Investigational Site | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01694771, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 3, 2014 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01694771 live on ClinicalTrials.gov.